Julian Baker portfolio · Q1 2026
Baker Bros. Advisors LP · CIK 0001263508 ·13F filings on SEC EDGAR
In Q1 2026, Baker Bros. Advisors LP reported 84 positions worth $17.4B. Its largest holding was INCY at 16.6% of the portfolio, and the top 10 made up 73%. Its largest new position was MIRM ($41.2M), and it sold out of RARE.
- NEW 7
- ADD 18
- REDUCE 6
- EXIT 9
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 44 positions are grouped as one box.
Portfolio history
Q4 2025 to Q1 2026, 2 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
INCY INCYTE CORP | 16.62% | $89.91* | $121.35 | +35.0% | $3.7B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ONC BEONE MEDICINES LTD-ADR | 15.00% | $136.93* | $365.94 | +167.2% | $3.2B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSM INSMED INC | 6.97% | $85.97* | $114.14 | +32.8% | $847M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDGL MADRIGAL PHARMACEUTICALS INC | 6.44% | $195.25 | $503.96 | +158.1% | $1.1B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACAD ACADIA PHARMACEUTICALS INC | 5.48% | $25.45* | $20.15 | -20.8% | $864.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 5.34% | $30.86 | $205.26 | +565.2% | $2B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CELC CELCUITY INC | 5.19% | $24.80 | $79.52 | +220.6% | $629.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KOD KODIAK SCIENCES INC | 4.36% | $33.47 | $94.80 | +183.2% | $1.9B |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KYMR KYMERA THERAPEUTICS INC | 4.14% | $37.07 | $111.79 | +201.6% | $967.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SMMT SUMMIT THERAPEUTICS INC | 3.96% | $12.42 | $16.91 | +36.1% | $615.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 3.24% | $208.46 | $291.23 | +39.7% | $510.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 2.80% | $24.92 | $95.22 | +282.1% | $533.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALKS ALKERMES PLC | 2.03% | $26.97 | $40.52 | +50.2% | $405.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GRAL GRAIL INC | 1.20% | $41.82 | $140.12 | +235.0% | $564.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 1.19% | $15.77 | $40.60 | +157.4% | $267M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.88% | $74.82 | $44.65 | -40.3% | $91.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KNSA KINIKSA PHARMACEUTICALS INTE | 0.78% | $18.70 | $74.61 | +298.9% | $210.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 0.78% | $21.09 | $33.78 | +60.2% | $184.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 0.77% | $13.76 | $36.57 | +165.7% | $178M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDYA IDEAYA BIOSCIENCES INC | 0.76% | $23.89 | $38.42 | +60.8% | $151.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARWR ARROWHEAD PHARMACEUTICALS IN | 0.72% | $33.82 | $65.45 | +93.5% | $130.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STOK STOKE THERAPEUTICS INC | 0.62% | $11.09 | $26.00 | +134.4% | $86.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMTX IMMATICS NV | 0.62% | $8.87 | $8.78 | -1.0% | $95.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABCL ABCELLERA BIOLOGICS INC | 0.61% | $17.24 | $14.59 | -15.4% | $441.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 0.56% | $84.90 | $99.02 | +16.6% | $86.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRNX CRINETICS PHARMACEUTICALS IN | 0.49% | $41.38 | $37.42 | -9.6% | $88M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REPL REPLIMUNE GROUP INC | 0.49% | $13.45 | $13.24 | -1.5% | $146.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
15102KAA8 Celcuity Inc. | 0.43% | $2.43 | $2.43 | 0.0% | $74.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 0.41% | $24.49 | $23.71 | -3.2% | $110.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNLI DENALI THERAPEUTICS INC | 0.41% | $23.61 | $20.67 | -12.4% | $77.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNTH DIANTHUS THERAPEUTICS INC | 0.41% | $23.41 | $88.05 | +276.1% | $75M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GLUE MONTE ROSA THERAPEUTICS INC | 0.41% | $6.13 | $11.93 | +94.7% | $51.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GPCR STRUCTURE THERAPEUTICS INC | 0.40% | $20.84 | $31.27 | +50.0% | $44.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRDA ENTRADA THERAPEUTICS INC | 0.37% | $16.68 | $6.35 | -61.9% | $32.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCYC BICYCLE THERAPEUTICS PLC-ADR | 0.29% | $20.78 | $3.68 | -82.3% | $40.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 0.29% | $15.64 | $89.03 | +469.3% | $89M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPP RAPPORT THERAPEUTICS INC | 0.28% | $23.18 | $33.60 | +44.9% | $52M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALMS ALUMIS INC | 0.25% | $15.25 | $7.39 | -51.5% | $14.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.24% | $92.38 | $85.48 | -7.5% | $38.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.22% | $15.96 | $20.59 | +29.0% | $40.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.20% | $32.34 | $45.84 | +41.7% | $41.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRLD PRELUDE THERAPEUTICS INC | 0.20% | $30.14 | $3.91 | -87.0% | $39.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.18% | $3.09 | $11.76 | +280.6% | $17.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DSGN DESIGN THERAPEUTICS INC | 0.16% | $9.41 | $12.57 | +33.6% | $32.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTA CENTESSA PHARMACEUTICALS LTD | 0.15% | $25.01 | $39.72 | +58.8% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.13% | $2.77 | $2.72 | -1.7% | $13.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JBIO JADE BIOSCIENCES INC | 0.13% | $15.43 | $14.05 | -8.9% | $23.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRON DISC MEDICINE INC | 0.13% | $55.66 | $65.46 | +17.6% | $22.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMCR IMMUNOCORE HOLDINGS PLC-ADR | 0.13% | $38.09 | $30.29 | -20.5% | $22.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 0.12% | $21.68 | $37.19 | +71.5% | $13.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLDX CELLDEX THERAPEUTICS INC | 0.12% | $22.62 | $32.41 | +43.3% | $21.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NGNE NEUROGENE INC | 0.11% | $12.31 | $27.82 | +126.0% | $27.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.11% | $22.99 | $8.26 | -64.1% | $7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECX TECTONIC THERAPEUTIC INC | 0.11% | $20.51 | $23.29 | +13.5% | $14.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.11% | $11.77 | $13.42 | +14.0% | $19.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARGX ARGENX SE - ADR | 0.11% | $79.01 | $958.91 | +1,113.7% | $24.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CERS CERUS CORP | 0.10% | $4.94* | $2.38 | -51.8% | $23.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 0.10% | $2.64 | $4.87 | +84.5% | $19.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AKTS AKTIS ONCOLOGY INC | 0.10% | $17.89 | $19.47 | +8.8% | $19.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GENB GENERATE BIOMEDICINES INC | 0.10% | $12.50 | $15.02 | +20.2% | $21.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 0.09% | $10.46 | $5.26 | -49.7% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 0.08% | $19.56 | $16.11 | -17.6% | $13.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 0.08% | $18.16 | $24.95 | +37.4% | $27.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMPS COMPASS PATHWAYS PLC | 0.07% | $5.53 | $12.44 | +125.0% | $29.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 0.07% | $13.52 | $18.05 | +33.5% | $20.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SERA SERA PROGNOSTICS INC-A | 0.06% | $5.59 | $2.09 | -62.6% | $11.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTX BIONTECH SE-ADR | 0.06% | $107.38 | $98.30 | -8.5% | $11.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHVS PHARVARIS NV | 0.06% | $24.95 | $31.72 | +27.1% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RCUS ARCUS BIOSCIENCES INC | 0.05% | $23.05 | $25.83 | +12.1% | $10.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MPLT MAPLIGHT THERAPEUTICS INC | 0.04% | $17.56 | $10.19 | -42.0% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABSI ABSCI CORP | 0.04% | $3.49 | $10.77 | +208.6% | $23M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Y95308105 WAVE LIFE SCIENCES LTD | 0.03% | $7.65 | $5.81 | -24.0% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTVT VTV THERAPEUTICS INC- CL A | 0.03% | $23.47 | $30.84 | +31.4% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EIKN EIKON THERAPEUTICS INC | 0.03% | $10.58 | $8.04 | -24.0% | $4.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARA PROTARA THERAPEUTIC INC | 0.03% | $7.12 | $3.05 | -57.2% | $3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGMT SAGIMET BIOSCIENCES INC-A | 0.03% | $7.31 | $9.88 | +35.1% | $9.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LBRX LB PHARMACEUTICALS INC | 0.03% | $15.79 | $38.38 | +143.1% | $7.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VSTM VERASTEM INC | 0.02% | $5.30 | $8.05 | +51.9% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TCRX TSCAN THERAPEUTICS INC | 0.02% | $5.80 | $0.31 | -94.6% | $875.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
83086J200 Skye Bioscience, Inc. | 0.01% | $4.94 | $0.69 | -86.0% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SANA SANA BIOTECHNOLOGY INC | 0.01% | $4.35 | $2.92 | -32.9% | $905.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALGS ALIGOS THERAPEUTICS INC | 0.00% | $8.66 | $5.63 | -35.0% | $467.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TYRA TYRA BIOSCIENCES INC | 0.00% | $13.85 | $21.87 | +57.9% | $232K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZNW SURROZEN INC-CW25 | 0.00% | — | $0.02 | — | $13.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Dec 31, 2025, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Dec 31, 2025 and not reported for Q1 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| RARE ULTRAGENYX PHARMACEUTICAL IN | 0.37% | 2,772,692 | $63.8M | EXIT |
| TERN TERNS PHARMACEUTICALS INC | 0.22% | 950,000 | $38.4M | EXIT |
| BCRX BIOCRYST PHARMACEUTICALS INC | 0.13% | 2,822,727 | $22M | EXIT |
| VTYX VENTYX BIOSCIENCES INC | 0.12% | 2,349,280 | $21.2M | EXIT |
| NUVL NUVALENT INC-A | 0.08% | 143,937 | $14.5M | EXIT |
| FDMT 4D MOLECULAR THERAPEUTICS IN | 0.02% | 475,737 | $3.6M | EXIT |
| VIR VIR BIOTECHNOLOGY INC | 0.02% | 542,539 | $3.3M | EXIT |
| 483119202 KALA BIO INC | 0.01% | 1,804,055 | $1M | EXIT |
| ACRV ACRIVON THERAPEUTICS INC | 0.00% | 22,809 | $55K | EXIT |
SEC filings for Q1 2026
- 13F-HR 0001104659-26-062547 · accepted May 15, 2026, 20:12 UTC